Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Microglial glutamate release evoked by α-synuclein aggregates is prevented by dopamine.

Dos-Santos-Pereira M, Acuña L, Hamadat S, Rocca J, González-Lizárraga F, Chehín R, Sepulveda-Diaz J, Del-Bel E, Raisman-Vozari R, Michel PP.

Glia. 2018 Nov;66(11):2353-2365. doi: 10.1002/glia.23472. Epub 2018 Nov 5.

PMID:
30394585
2.

Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop.

Mouton-Liger F, Rosazza T, Sepulveda-Diaz J, Ieang A, Hassoun SM, Claire E, Mangone G, Brice A, Michel PP, Corvol JC, Corti O.

Glia. 2018 Apr 17. doi: 10.1002/glia.23337. [Epub ahead of print]

3.

Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons.

Wagner J, Vulinović F, Grünewald A, Unger MM, Möller JC, Klein C, Michel PP, Ries V, Oertel WH, Alvarez-Fischer D.

Neuroscience. 2017 Dec 4;365:137-145. doi: 10.1016/j.neuroscience.2017.09.045. Epub 2017 Oct 4.

PMID:
28987508
4.

Correction to Identification of a Novel 1,4,8-Triazaphenanthrene Derivative as a Neuroprotectant for Dopamine Neurons Vulnerable in Parkinson's Disease.

Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Séon-Méniel B, Acuña L, Raisman-Vozari R, Michel PP, Figadère B.

ACS Chem Neurosci. 2017 Oct 18;8(10):2347. doi: 10.1021/acschemneuro.7b00352. Epub 2017 Sep 27. No abstract available.

PMID:
28953349
5.

The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons.

Lavaur J, Le Nogue D, Lemaire M, Pype J, Farjot G, Hirsch EC, Michel PP.

J Neurochem. 2017 Jul;142(1):14-28. doi: 10.1111/jnc.14041. Epub 2017 May 16.

6.

Identification of a Novel 1,4,8-Triazaphenanthrene Derivative as a Neuroprotectant for Dopamine Neurons Vulnerable in Parkinson's Disease.

Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B.

ACS Chem Neurosci. 2017 Jun 21;8(6):1222-1231. doi: 10.1021/acschemneuro.6b00385. Epub 2017 Feb 15. Erratum in: ACS Chem Neurosci. 2017 Oct 18;8(10 ):2347.

PMID:
28140556
7.

Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress.

Lavaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP.

Cell Death Discov. 2016 May 16;2:16018. doi: 10.1038/cddiscovery.2016.18. eCollection 2016.

8.

A simplified approach for efficient isolation of functional microglial cells: Application for modeling neuroinflammatory responses in vitro.

Sepulveda-Diaz JE, Ouidja MO, Socias SB, Hamadat S, Guerreiro S, Raisman-Vozari R, Michel PP.

Glia. 2016 Nov;64(11):1912-24. doi: 10.1002/glia.23032. Epub 2016 Jul 25.

PMID:
27452488
9.

New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.

Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B.

J Med Chem. 2016 Jul 14;59(13):6169-86. doi: 10.1021/acs.jmedchem.6b00297. Epub 2016 Jul 5.

PMID:
27341519
10.

The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.

Gautier CA, Erpapazoglou Z, Mouton-Liger F, Muriel MP, Cormier F, Bigou S, Duffaure S, Girard M, Foret B, Iannielli A, Broccoli V, Dalle C, Bohl D, Michel PP, Corvol JC, Brice A, Corti O.

Hum Mol Genet. 2016 Jul 15;25(14):2972-2984. Epub 2016 May 19.

PMID:
27206984
11.

Understanding Dopaminergic Cell Death Pathways in Parkinson Disease.

Michel PP, Hirsch EC, Hunot S.

Neuron. 2016 May 18;90(4):675-91. doi: 10.1016/j.neuron.2016.03.038. Review.

12.

Neuroprotective and neurorestorative potential of xenon.

Lavaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP.

Cell Death Dis. 2016 Apr 7;7:e2182. doi: 10.1038/cddis.2016.86. No abstract available.

13.

Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Santos DB, Colle D, Moreira EL, Hort MA, Godoi M, Le Douaron G, Braga AL, Assreuy J, Michel PP, Prediger RD, Raisman-Vozari R, Farina M.

Mol Neurobiol. 2017 Mar;54(2):1513-1530. doi: 10.1007/s12035-016-9747-z. Epub 2016 Feb 6.

PMID:
26852411
14.

Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways.

Santa-Cecília FV, Socias B, Ouidja MO, Sepulveda-Diaz JE, Acuña L, Silva RL, Michel PP, Del-Bel E, Cunha TM, Raisman-Vozari R.

Neurotox Res. 2016 May;29(4):447-59. doi: 10.1007/s12640-015-9592-2. Epub 2016 Jan 8.

PMID:
26745968
15.

Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.

Bensaid M, Michel PP, Clark SD, Hirsch EC, François C.

Exp Neurol. 2016 Jan;275 Pt 1:209-19. doi: 10.1016/j.expneurol.2015.11.004. Epub 2015 Nov 10.

PMID:
26571193
16.

Piperazine derivatives as iron chelators: a potential application in neurobiology.

Abdelsayed S, Duong NT, Bureau C, Michel PP, Hirsch EC, Chahine JM, Serradji N.

Biometals. 2015 Dec;28(6):1043-61. doi: 10.1007/s10534-015-9889-x.

PMID:
26502356
17.

Signaling Mechanisms in the Nitric Oxide Donor- and Amphetamine-Induced Dopamine Release in Mesencephalic Primary Cultured Neurons.

Salum C, Schmidt F, Michel PP, Del-Bel E, Raisman-Vozari R.

Neurotox Res. 2016 Jan;29(1):92-104. doi: 10.1007/s12640-015-9562-8. Epub 2015 Sep 21.

PMID:
26391887
18.

Acceleration of conduction velocity linked to clustering of nodal components precedes myelination.

Freeman SA, Desmazières A, Simonnet J, Gatta M, Pfeiffer F, Aigrot MS, Rappeneau Q, Guerreiro S, Michel PP, Yanagawa Y, Barbin G, Brophy PJ, Fricker D, Lubetzki C, Sol-Foulon N.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):E321-8. doi: 10.1073/pnas.1419099112. Epub 2015 Jan 5.

19.

The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine.

Guerreiro S, Florence C, Rousseau E, Hamadat S, Hirsch EC, Michel PP.

Mol Pharmacol. 2015;87(3):525-32. doi: 10.1124/mol.114.095703. Epub 2014 Dec 31.

20.

Neuroprotective effects of a brain permeant 6-aminoquinoxaline derivative in cell culture conditions that model the loss of dopaminergic neurons in Parkinson disease.

Le Douaron G, Schmidt F, Amar M, Kadar H, Debortoli L, Latini A, Séon-Méniel B, Ferrié L, Michel PP, Touboul D, Brunelle A, Raisman-Vozari R, Figadère B.

Eur J Med Chem. 2015 Jan 7;89:467-79. doi: 10.1016/j.ejmech.2014.10.067. Epub 2014 Oct 23.

PMID:
25462259
21.

Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.

Bensaid M, Tandé D, Fabre V, Michel PP, Hirsch EC, François C.

Eur J Neurosci. 2015 Jan;41(1):129-36. doi: 10.1111/ejn.12761. Epub 2014 Oct 18.

PMID:
25328140
22.

Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.

Noelker C, Morel L, Osterloh A, Alvarez-Fischer D, Lescot T, Breloer M, Gold M, Oertel WH, Henze C, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A.

J Neuroinflammation. 2014 May 8;11:86. doi: 10.1186/1742-2094-11-86.

23.

The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis.

Rousseau E, Michel PP, Hirsch EC.

Mol Pharmacol. 2013 Dec;84(6):888-98. doi: 10.1124/mol.113.087965. Epub 2013 Sep 27.

24.

Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.

Alvarez-Fischer D, Noelker C, Grünewald A, Vulinović F, Guerreiro S, Fuchs J, Lu L, Lombès A, Hirsch EC, Oertel WH, Michel PP, Hartmann A.

J Neurochem. 2013 Dec;127(6):782-92. doi: 10.1111/jnc.12343. Epub 2013 Jul 8.

25.

Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease.

Michel PP, Toulorge D, Guerreiro S, Hirsch EC.

FASEB J. 2013 Sep;27(9):3414-23. doi: 10.1096/fj.12-220418. Epub 2013 May 22. Review.

PMID:
23699175
26.

Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model.

Alvarez-Fischer D, Noelker C, Vulinović F, Grünewald A, Chevarin C, Klein C, Oertel WH, Hirsch EC, Michel PP, Hartmann A.

PLoS One. 2013 Apr 18;8(4):e61700. doi: 10.1371/journal.pone.0061700. Print 2013.

27.

Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease.

Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A.

Sci Rep. 2013;3:1393. doi: 10.1038/srep01393.

28.

Flavaglines as potent anticancer and cytoprotective agents.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Désaubry L.

J Med Chem. 2012 Nov 26;55(22):10064-73. doi: 10.1021/jm301201z. Epub 2012 Oct 23.

PMID:
23072299
29.

Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.

Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP.

FASEB J. 2011 Aug;25(8):2563-73. doi: 10.1096/fj.11-182824. Epub 2011 Apr 20.

PMID:
21507900
30.

Methylxanthines and ryanodine receptor channels.

Guerreiro S, Marien M, Michel PP.

Handb Exp Pharmacol. 2011;(200):135-50. doi: 10.1007/978-3-642-13443-2_5. Review.

PMID:
20859795
31.

KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis.

Toulorge D, Guerreiro S, Hirsch EC, Michel PP.

J Neurochem. 2010 Jul;114(2):553-64. doi: 10.1111/j.1471-4159.2010.06785.x. Epub 2010 Apr 29.

32.

Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization.

Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, Michel PP.

J Neurochem. 2009 May;109(4):1118-28. doi: 10.1111/j.1471-4159.2009.06040.x. Epub 2009 Mar 19.

33.

Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin.

Lannuzel A, Ruberg M, Michel PP.

Mov Disord. 2008 Nov 15;23(15):2122-8. doi: 10.1002/mds.22300. Review.

PMID:
18816693
34.

Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.

Alvarez-Fischer D, Guerreiro S, Hunot S, Saurini F, Marien M, Sokoloff P, Hirsch EC, Hartmann A, Michel PP.

J Neurochem. 2008 Nov;107(3):701-11. doi: 10.1111/j.1471-4159.2008.05651.x. Epub 2008 Sep 16.

35.

Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels.

Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, Michel PP.

Mol Pharmacol. 2008 Oct;74(4):980-9. doi: 10.1124/mol.108.048207. Epub 2008 Jul 11.

36.

Modulation of dopamine uptake by nitric oxide in cultured mesencephalic neurons.

Salum C, Raisman-Vozari R, Michel PP, Gomes MZ, Mitkovski M, Ferrario JE, Ginestet L, Del Bel EA.

Brain Res. 2008 Mar 10;1198:27-33. doi: 10.1016/j.brainres.2007.12.054. Epub 2008 Jan 3.

PMID:
18255050
37.

Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.

Escobar-Khondiker M, Höllerhage M, Muriel MP, Champy P, Bach A, Depienne C, Respondek G, Yamada ES, Lannuzel A, Yagi T, Hirsch EC, Oertel WH, Jacob R, Michel PP, Ruberg M, Höglinger GU.

J Neurosci. 2007 Jul 18;27(29):7827-37.

38.

Glia protects neurons against extracellular human neuromelanin.

Depboylu C, Matusch A, Tribl F, Zoriy M, Michel PP, Riederer P, Gerlach M, Becker S, Oertel WH, Höglinger GU.

Neurodegener Dis. 2007;4(2-3):218-26.

PMID:
17596716
39.

KAMEDO report no. 85: collapse of building during wedding reception in Jerusalem, 2001.

Michel PP, Sylvan A, Brändström H, Magnusson E.

Prehosp Disaster Med. 2007 Jan-Feb;22(1):80-2.

PMID:
17484368
40.

Role of activity-dependent mechanisms in the control of dopaminergic neuron survival.

Michel PP, Alvarez-Fischer D, Guerreiro S, Hild A, Hartmann A, Hirsch EC.

J Neurochem. 2007 Apr;101(2):289-97. Review.

41.

The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease.

Höglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, Boutillier AL, Degregori J, Oertel WH, Rakic P, Hirsch EC, Hunot S.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3585-90. Epub 2007 Feb 21.

42.

Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?

Lannuzel A, Höglinger GU, Champy P, Michel PP, Hirsch EC, Ruberg M.

J Neural Transm Suppl. 2006;(70):153-7.

PMID:
17017523
43.
45.

The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy.

Höglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Féger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC.

J Neurochem. 2005 Nov;95(4):930-9. Epub 2005 Aug 10.

47.
48.

Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro.

Henze C, Lescot T, Traver S, Salthun-Lassalle B, Hirsch EC, Michel PP, Hartmann A.

Neurosci Lett. 2005 Jul 22-29;383(1-2):44-8. Epub 2005 Apr 13.

PMID:
15936509
49.

The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress.

Traver S, Salthun-Lassalle B, Marien M, Hirsch EC, Colpaert F, Michel PP.

Mol Pharmacol. 2005 Jun;67(6):1882-91. Epub 2005 Mar 22.

50.

Experimental evidence for a toxic etiology of tropical parkinsonism.

Höglinger GU, Michel PP, Champy P, Feger J, Hirsch EC, Ruberg M, Lannuzel A.

Mov Disord. 2005 Jan;20(1):118-9. No abstract available.

PMID:
15390126

Supplemental Content

Loading ...
Support Center